Subtype
Female Reproductive System Neoplasm
CI-CAN-00000885Explore in graph →
Non-malignant1,630 active trials11 approved drugs139 evidence items
Loading cancer entity…
Subtype
CI-CAN-00000885Explore in graph →
Clinical trials
7,171 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02431559 | Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer | completed | Phase 1 / Phase 2 | 53 | Ludwig Institute for Cancer ResearchOTHER | 2 | Oct 10, 2022 | clinicaltrials |
| NCT00188695 | Combidex USPIO - Ultra-small Superparamagnetic Iron Oxide | completed | Phase 1 / Phase 2 | 61 | University Health Network, TorontoOTHER | 1 | Oct 7, 2022 | clinicaltrials |
| NCT02440425 | Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer | completed | Phase 2 | 42 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 7, 2022 | clinicaltrials |
| NCT03470805 | Olaparib After Response to Trabectedin-pegylated Liposomal Doxorubicin in Recurrent Ovarian Carcinoma | completed | Phase 2 | 9 | Grupo Español de Investigación en Cáncer de OvarioOTHER | 1 | Sep 23, 2022 | clinicaltrials |
| NCT02354586 | A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens(QUADRA) | completed | Phase 2 | 463 | Tesaro, Inc.INDUSTRY | 2 | Sep 15, 2022 | clinicaltrials |
| NCT02865811 | Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer | completed | Phase 2 | 26 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 13, 2022 | clinicaltrials |
| NCT02307500 | Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy(RESOUND) | completed | Phase 2 | 82 | Istituto Clinico HumanitasOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT02354131 | Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian Cancer(AVANOVA) | completed | Phase 1 / Phase 2 | 108 | Nordic Society of Gynaecological Oncology - Clinical Trials UnitOTHER | 2 | Aug 30, 2022 | clinicaltrials |
| NCT04392102 | A Study of Niraparib in Patients With Relapsed Ovarian Cancer | completed | Phase 2 | 15 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 1 | Aug 29, 2022 | clinicaltrials |
| NCT03394027 | ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma | completed | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Aug 23, 2022 | clinicaltrials |
| NCT03414047 | A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer | completed | Phase 2 | 172 | Eli Lilly and CompanyINDUSTRY | 8 | Aug 19, 2022 | clinicaltrials |
| NCT01590017 | Cisplatin and Radiation Therapy in Treating Patients With HIV-Associated Locally Advanced Cervical Cancer | completed | Phase 2 | 41 | AIDS Malignancy ConsortiumNETWORK | 2 | Jul 27, 2022 | clinicaltrials |
| NCT03029598 | Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 / Phase 2 | 29 | University of WashingtonOTHER | 1 | Jul 26, 2022 | clinicaltrials |
| NCT02529930 | An Exploratory Safety and Immunogenicity Study of HPV16+ Immunotherapy VB10.16 in Women With HSIL; CIN 2/3) | completed | Phase 1 / Phase 2 | 34 | Nykode Therapeutics ASAINDUSTRY | 1 | Jul 13, 2022 | clinicaltrials |
| NCT01809379 | Intraperitoneal Aerosol High-pressure Chemotherapy for Women With Recurrent Ovarian Cancer | completed | Phase 2 | 69 | Ruhr University of BochumOTHER | 1 | Jul 8, 2022 | clinicaltrials |
| NCT03562897 | Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer | completed | Phase 2 | 40 | Catalysis SLINDUSTRY | 1 | Jul 6, 2022 | clinicaltrials |
| NCT02317705 | Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer | completed | Phase 2 | 48 | On Target Laboratories, LLCINDUSTRY | 1 | Jun 21, 2022 | clinicaltrials |
| NCT02736305 | Use of Regorafenib in Recurrent Epithelial Ovarian Cancer | completed | Phase 2 | 21 | National Cancer Centre, SingaporeOTHER | 1 | Jun 13, 2022 | clinicaltrials |
| NCT03365791 | PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies | completed | Phase 2 | 76 | Novartis PharmaceuticalsINDUSTRY | 1 | May 27, 2022 | clinicaltrials |
| NCT00432094 | Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors | completed | Phase 2 | 23 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | May 17, 2022 | clinicaltrials |
| NCT04436133 | Immunogenicity AND Safety Study of the 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) | completed | Phase 2 | 480 | National Vaccine and Serum Institute, ChinaINDUSTRY | 1 | May 6, 2022 | clinicaltrials |
| NCT02107937 | Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma | completed | Phase 2 | 136 | SOTIO a.s.INDUSTRY | 2 | May 4, 2022 | clinicaltrials |
| NCT00181701 | Intraperitoneal Paclitaxel and Carboplatin in the Treatment of Women With Carcinoma of Mullerian Origin | completed | Phase 2 | 46 | Massachusetts General HospitalOTHER | 0 | Apr 14, 2022 | clinicaltrials |
| NCT02983799 | Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status | completed | Phase 2 | 272 | AstraZenecaINDUSTRY | 2 | Apr 13, 2022 | clinicaltrials |
| NCT00853307 | MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal Carcinoma | completed | Phase 2 | 31 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 8, 2022 | clinicaltrials |
| NCT02111850 | T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive | completed | Phase 1 / Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Mar 29, 2022 | clinicaltrials |
| NCT02674061 | Efficacy and Safety Study of Pembrolizumab (MK-3475) in Participants With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100) | completed | Phase 2 | 376 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 24, 2022 | clinicaltrials |
| NCT02608684 | A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer(PemCiGem) | completed | Phase 2 | 21 | Cedars-Sinai Medical CenterOTHER | 1 | Mar 23, 2022 | clinicaltrials |
| NCT04188847 | First-line Chemotherapy for Recurrent Cervical Cancer | completed | Phase 2 | 37 | Lei LiOTHER | 1 | Mar 15, 2022 | clinicaltrials |
| NCT04188860 | Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy | completed | Phase 2 | 34 | Lei LiOTHER | 1 | Mar 15, 2022 | clinicaltrials |
| NCT02889900 | Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer(CONCERTO) | completed | Phase 2 | 62 | AstraZenecaINDUSTRY | 1 | Mar 8, 2022 | clinicaltrials |
| NCT02549209 | Pembro/Carbo/Taxol in Endometrial Cancer | completed | Phase 2 | 46 | Daniela Matei, MDOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT02728258 | Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer | completed | Phase 2 | 11 | NRG OncologyOTHER | 1 | Feb 15, 2022 | clinicaltrials |
| NCT02178722 | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | completed | Phase 1 / Phase 2 | 444 | Incyte CorporationINDUSTRY | 1 | Feb 14, 2022 | clinicaltrials |
| NCT01307631 | Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Feb 11, 2022 | clinicaltrials |
| NCT00096200 | Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Feb 8, 2022 | clinicaltrials |
| NCT00317772 | Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer | completed | Phase 1 / Phase 2 | 19 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 7, 2022 | clinicaltrials |
| NCT00886691 | Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 150 | GOG FoundationNETWORK | 1 | Feb 4, 2022 | clinicaltrials |
| NCT05149248 | Prevention and Control of Neoplasms Associated With HPV in High-risk Groups in Mexico City: The Condesa Study(CONDESA) | completed | Phase 2 / Phase 3 | 6,000 | Instituto Nacional de Salud Publica, MexicoOTHER | 1 | Dec 8, 2021 | clinicaltrials |
| NCT02764333 | TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer | completed | Phase 2 | 29 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 30, 2021 | clinicaltrials |
| NCT01512810 | Intraoperative Pathological Evaluation for Surgical Treatment & Staging for Endometrial Cancer | completed | Phase 2 | 200 | Frederick R. Ueland, M.D.OTHER | 1 | Nov 24, 2021 | clinicaltrials |
| NCT02725268 | A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer | completed | Phase 2 | 241 | Millennium Pharmaceuticals, Inc.INDUSTRY | 10 | Nov 24, 2021 | clinicaltrials |
| NCT02657928 | Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer | completed | Phase 2 | 40 | Mayo ClinicOTHER | 1 | Oct 26, 2021 | clinicaltrials |
| NCT00888615 | Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 58 | GOG FoundationNETWORK | 1 | Oct 20, 2021 | clinicaltrials |
| NCT01720173 | Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | completed | Phase 2 | 30 | Gynecologic Oncology GroupNETWORK | 1 | Oct 20, 2021 | clinicaltrials |
| NCT01551745 | Salvage Ovarian FANG™ Vaccine + Bevacizumab | completed | Phase 2 | 5 | Gradalis, Inc.INDUSTRY | 1 | Oct 19, 2021 | clinicaltrials |
| NCT01853644 | Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer(TIVO) | completed | Phase 2 | 31 | Northwestern UniversityOTHER | 1 | Oct 12, 2021 | clinicaltrials |
| NCT02853318 | Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 40 | Roswell Park Cancer InstituteOTHER | 1 | Oct 6, 2021 | clinicaltrials |
| NCT03276013 | Pembrolizumab in Combination With Doxorubicin in Advanced, Recurrent or Metastatic Endometrial Cancer(TOPIC) | completed | Phase 2 | 48 | Vall d'Hebron Institute of OncologyOTHER | 1 | Oct 5, 2021 | clinicaltrials |
| NCT04453241 | Immunogenicity and Safety Study of NBP615 in Healthy Female | completed | Phase 1 / Phase 2 | 200 | SK Bioscience Co., Ltd.INDUSTRY | 1 | Oct 1, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Oct 10, 2022source: clinicaltrials